TOP1 and neoplasm: This dual targeting of TS/Top1 by F10 results in potent anti-tumor activity, which we have demonstrated occurs in multiple pre-clinical models of AML[55], acute lymphocytic leukemia[48], prostate cancer[56], glioblastoma[57], colorectal cancer, and pancreatic ductal adenocarcinoma.